IonQ Unveils Its First Quantum Computer in Europe, Online Now at a Record #AQ36
5.12.2024 14:05:00 CET | Business Wire | Press release
IonQ’s quantum computer Forte Enterprise has achieved the record-breaking milestone of #AQ36In partnership with QuantumBasel, IonQ Forte Enterprise will provide European Enterprise Customers, Industries, government entities, and research institutes with local access to IonQ’s most powerful quantum systemsIonQ has opened its First European Innovation Center at the uptownBasel campus in Arlesheim, Switzerland
IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the delivery of IonQ Forte Enterprise to its first European Innovation Center at the uptownBasel campus in Arlesheim, Switzerland. Achieved in partnership with QuantumBasel, this major milestone marks the first datacenter-ready quantum computer IonQ has delivered that will operate outside the United States and the first quantum system for commercial use in Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205805000/en/

IonQ European Innovation Center - Arlesheim, Switzerland (Photo: Business Wire)
Forte Enterprise is now online servicing compute jobs while performing at a record algorithmic qubit count of #AQ36, which is significantly more powerful than the promised #AQ35. With each additional #AQ, the useful computational space for running quantum algorithms doubles. A system with #AQ36 is capable of considering more than 68 billion different possibilities simultaneously. With this milestone, IonQ once again leads the industry in delivering production-ready systems to customers.
“The successful commissioning of Forte Enterprise in Europe – on schedule and at an even higher performance level than announced previously – demonstrates IonQ’s commitment to driving global quantum adoption through technological leadership and operational excellence,” said Peter Chapman, CEO and President of IonQ. “Achieving #AQ36 is a significant leap forward, opening new possibilities for applications including logistics, finance, pharmaceuticals, chemistry and artificial intelligence.”
“Offering the state-of-the-art Forte Enterprise quantum computing platform to our ecosystem will accelerate the development of quantum applications across a range of fields,” said Damir Bogdan, CEO of QuantumBasel. “By collaborating with IonQ, we’re positioning the uptownBasel campus as a leader in quantum innovation, fostering breakthroughs that address real-world challenges.”
IonQ’s next generation commercial quantum systems such as Forte Enterprise are optimized for data center environments, sporting a rack-mounted form factor, low energy profile, and minimal environmental isolation requirements.
Building on a History of Excellence
Today’s IonQ Forte Enterprise system commissioning represents the culmination of IonQ’s engineering innovation, operational excellence, and enterprise-grade production capabilities.
“This milestone reflects the hard work and ingenuity of teams across IonQ and QuantumBasel,” said Dr. Dave Mehuys, VP of Production Engineering. “We aligned our system build with on-site datacenter construction and IonQ’s manufacturing and production teams leveraged their decades of expertise to bring this groundbreaking system online faster than anticipated.”
Pioneering a New Era of Computing
IonQ’s record-breaking achievement of #AQ36 signals the company’s dedication and success in advancing quantum performance. Forte Enterprise expands the potential for driving groundbreaking research in areas such as quantum chemistry and machine learning.
“IonQ’s ability to deliver Forte Enterprise with #AQ36 reflects our growing capabilities to execute on our mission to drive significant quantum advancements globally,” said Dr. Dean Kassmann, Senior Vice President of Engineering and Technology at IonQ. “Each step we take demonstrates our commitment to bringing quantum computing from the lab to practical, impactful, and commercial uses.”
A Quantum Leap for Europe and Beyond
IonQ’s first European Innovation Center will allow the company to service its European customers out of its QuantumBasel location and to drive research and development of next generation quantum applications in Europe.
As part of its partnership with IonQ, QuantumBasel will offer its ecosystem– including enterprises, research institutes, startups, and universities – direct access to the #AQ36 Forte Enterprise system.
With datacenters now in the Washington, D.C., Seattle, and Basel, Switzerland areas, IonQ has firmly established a global data center footprint, reinforcing its position as a leader in quantum technology.
To learn more about IonQ’s latest innovations, visit www.ionq.com.
About IonQ
IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
About QuantumBasel
QuantumBasel is a competence center for quantum computing and AI and drives access to commercial quantum computing to foster innovation. QuantumBasel places particular emphasis on technological neutrality and is Switzerland’s first commercial quantum computing hub, providing access to hardware from IBM, D-Wave and IonQ. QuantumBasel’s team of quantum and data scientists trains and supports companies, conducts projects in quantum computing and AI, and collaborates closely with universities and academic institutions. Through an internationally connected ecosystem, QuantumBasel provides access to advanced know-how and technologies, enabling companies in industrial production, logistics, finance, energy, life sciences, and start-ups to achieve innovations they cannot develop independently. www.quantumbasel.com
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the terms “adoption,” “advancing,” “advancements,” “collaborating,” “commitment,” “demonstrates,” “development,” “groundbreaking” “milestone,” “next generation,” “optimized,” “potential,” “significant leap forward,” “state-of-the-art,” “will,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the company’s technology driving commercial quantum advantage in the future, the timing of delivering to customers IonQ Forte Enterprise systems, the planned increase to the footprint of the uptownBasel campus in Arlesheim, Switzerland, the company’s ability to establish public-private partnerships, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, access to IonQ’s quantum computers, the ability to test and execute quantum applications on IonQ’s quantum computers, the opportunity to test and optimize novel quantum-enhanced algorithms for computational challenges on IonQ’s quantum computers; the problems that can be solved by IonQ’s quantum computers, the advantages of IonQ's approach to the manufacturing of IonQ’s systems, IonQ’s quantum computing capabilities and plans, and the scalability and reliability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive industries in which IonQ operates; the ability of IonQ to protect its intellectual property; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, technical roadmap, and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers; or market adoption of quantum computing solutions and IonQ’s products, services and solutions. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205805000/en/


Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom